BiotechTube
Dot Decimal

Dot Decimal

Raleigh, United States· Est.
dotdecimal.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2015 and headquartered in Sanford, Florida (with a listed office in Raleigh, NC), Dot Decimal operates at the intersection of medical devices and software in the radiation oncology sector. The company has established a significant commercial footprint, having produced over 532,000 devices for more than 151,000 patients. Its business model is service-oriented, providing custom-fabricated treatment accessories and associated software tools directly to cancer treatment clinics, positioning it as a critical infrastructure partner in the precision radiation therapy workflow.

Oncology

Technology Platform

Integrated platform for precision manufacturing of patient-specific beam-shaping devices (bolus, apertures, compensators) coupled with proprietary software for radiation oncology planning, dose-based device design, and quality assurance.

Opportunities

Significant growth opportunity lies in international expansion beyond the established U.S.
base and in developing integrated device/software solutions for emerging radiotherapy techniques like GRID therapy and FLASH radiotherapy.
Deepening partnerships with radiation system OEMs could also drive further market penetration.

Risk Factors

Key risks include market saturation in the U.S., technological disruption from in-clinic 3D printing, and potential reimbursement pressure on radiation therapy procedures that could squeeze margins.
The company is also exposed to regulatory changes for medical device manufacturing.

Competitive Landscape

Dot Decimal competes with other custom radiation device manufacturers (e.g., CIVCO, Orfit Industries) and in-house clinic fabrication shops. Its key differentiators are its multi-modality (photon, electron, proton) support, integrated software platform, and demonstrated scale. The competitive threat from clinics adopting their own 3D printers for bolus is growing.

More companies in Radiopharmaceuticals →More companies in United States →